Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge

Next Previous
Trial Profile

A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vapendavir (Primary)
  • Indications Rhinovirus infections
  • Focus Therapeutic Use
  • Sponsors Altesa Biosciences

Most Recent Events

  • 24 Jul 2025 According to Altesa BioSciences media release, Based on resultsfrom this trial, company is planning to conduct a multicenter, multinational, randomized controlled Phase 2b trial in COPD patients experiencing natural rhinovirus infections. The trial will begin in early 2026 and conclude and have topline results available in late 2027.
  • 24 Jul 2025 According to Altesa BioSciences media release, company announced that its abstract has been selected for a late-breaker presentation at the European Respiratory Society (ERS) International Congress 2025 in Amsterdam on September 30, 2025 at 8 AM CEST.
  • 07 May 2025 Results presented in the Altesa BioSciences Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top